샤가스병 치료 시장 규모, 점유율 및 성장 분석 : 치료법별, 병기별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Chagas Disease Treatment Market size was valued at USD 11.41 Billion in 2024 and is poised to grow from USD 12.23 Billion in 2025 to USD 21.33 Billion by 2033, growing at a CAGR of 7.2% during the forecast period (2026-2033).

The global Chagas disease treatment market has emerged as a significant public health concern due to the migration of infected individuals from endemic regions in Latin America to North America and Europe. This market encompasses antiparasitic medications, diagnostic tests, and supportive treatments essential for managing Trypanosoma cruzi infections, as untreated cases can result in severe health complications, placing additional strain on healthcare systems. Increased international attention toward Chagas disease has been driven by enhanced surveillance, screening initiatives, and regulatory advancements that broaden access in non-endemic areas. Market dynamics are influenced by improvements in testing capacity, which raise demand and prompt healthcare facilities to adjust procurement strategies. Public-private partnerships and targeted product development are fostering innovations that facilitate the rapid dissemination of interventions worldwide, creating opportunities for manufacturers and NGOs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chagas Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Chagas Disease Treatment Market Segments Analysis

The global Chagas disease treatment market is segmented by treatment type, disease stage, route of administration, end user, distribution channel, and region. Treatment categories include antiparasitic medications, symptomatic care, and others. Based on the disease stage, the market is divided into acute and chronic phases. Routes of administration include oral and intravenous options. End users include hospitals and clinics, specialized tropical disease centers, and others. Distribution channels consist of hospital pharmacies, retail pharmacies, and online healthcare platforms. Regionally, the market spans North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Chagas Disease Treatment Market

One of the key market drivers for the global Chagas disease treatment market is the increasing awareness and initiatives aimed at the diagnosis and treatment of neglected tropical diseases, including Chagas disease. Enhanced global health collaborations and funding from governmental and non-governmental organizations are promoting research and development of effective therapies and diagnostic tools. Additionally, rising prevalence rates in endemic areas, coupled with improved healthcare infrastructure, are contributing to a greater emphasis on Chagas disease treatment. This growing recognition and commitment to tackling Chagas disease are driving investments and innovations in therapeutic options, ultimately boosting market growth.

Restraints in the Global Chagas Disease Treatment Market

One key market restraint for the global Chagas disease treatment market is the lack of awareness and education among both healthcare professionals and the general population regarding the disease. Chagas disease is often asymptomatic in its early stages, leading to underdiagnosis and undertreatment. Additionally, many affected individuals may reside in remote or underserved regions where healthcare access is limited. This ignorance can result in delayed treatment and insufficient research investments, ultimately hindering the development and availability of effective therapies. Consequently, this gap in knowledge and healthcare infrastructure poses a significant barrier to the growth of the Chagas disease treatment market.

Market Trends of the Global Chagas Disease Treatment Market

The Global Chagas Disease Treatment market is experiencing a significant upward trend driven by an expanding integration of screening programs into healthcare systems. This shift enhances the identification of cases through collaborative efforts between primary care providers, NGOs, and public health agencies, resulting in a more streamlined patient journey from diagnosis to treatment. Local services are leveraging these screening initiatives to facilitate early detection and ensure tailored treatment pathways while respecting community customs. The emerging decentralized healthcare model promotes comprehensive, integrated care that encompasses diagnostics, therapeutic interventions, and long-term patient follow-up, ultimately improving treatment adherence and outcomes in affected populations.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Chagas Disease Treatment Market Size by Treatment Modality & CAGR (2026-2033)

• Market Overview
• Antiparasitic Medication
  • Benznidazole
  • Nifurtimox
• Symptomatic Treatment
  • Heart Failure Management
  • Digestive System Treatment
• Others

Global Chagas Disease Treatment Market Size by Disease Phase & CAGR (2026-2033)

• Market Overview
• Acute Phase
• Chronic Phase
• Others

Global Chagas Disease Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous
• Others

Global Chagas Disease Treatment Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals and Clinics
• Specialized Tropical Medicine Centers
• Others

Global Chagas Disease Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Healthcare Platforms
• Others

Global Chagas Disease Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Modality, Disease Phase, Route of Administration, End-User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Modality, Disease Phase, Route of Administration, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Modality, Disease Phase, Route of Administration, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Modality, Disease Phase, Route of Administration, End-User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Modality, Disease Phase, Route of Administration, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Bayer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chemo Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mundipharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mankind Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DNDi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bensaude Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Savior Lifesciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratorios ELEA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations